Source comparison
MK-677 vs Sermorelin: Direct Comparison
The table below maps the core pharmacological, administrative, and mechanistic distinctions between the two compounds. Mechanism Ghrelin receptor agonist (GHSR1a). Bypasses GHRH pathway GHRH receptor agonist on pituitary somatotrophs. Requires intact hypothala
This comparison does not assign a generated winner or score.
- The table below maps the core pharmacological, administrative, and mechanistic distinctions between the two compounds.
- Mechanism
- Ghrelin receptor agonist (GHSR1a). Bypasses GHRH pathway
- GHRH receptor agonist on pituitary somatotrophs. Requires intact hypothalamic-pituitary axis
- MK-677 functions independently of pituitary health; Sermorelin requires functional GHRH receptors
- Administration
- Oral capsule or liquid suspension
- Subcutaneous injection (typically abdominal or thigh)
- MK-677 offers convenience advantage; Sermorelin requires injection training and sterile technique
- Half-Life
- 4–6 hours (plasma); 24-hour pharmacodynamic effect
- 10–12 minutes (plasma); 2–3 hour GH pulse duration
- MK-677 sustains GH elevation; Sermorelin produces transient pulsatile secretion
- GH Secretion Pattern
- Non-pulsatile, sustained elevation over 24 hours
- Pulsatile secretion mirroring endogenous nocturnal GH surge
- Sermorelin preserves physiological pulsatility; MK-677 creates supraphysiological steady-state
- IGF-1 Elevation
- 60–90% above baseline (chronic dosing at 10–25mg/day)
- 30–50% above baseline (nightly dosing at 200–300mcg)
- MK-677 produces greater magnitude IGF-1 increase; Sermorelin elevation is more modest
- Storage Requirements
- Stable at room temperature as powder; store away from moisture and light
- Lyophilised peptide must be stored at −20°C; reconstituted solution refrigerated at 2–8°C, use within 30 days
- MK-677 requires minimal cold chain; Sermorelin demands strict temperature control
- Pituitary Dependency
- No. Works even with pituitary insufficiency
- Yes. Requires functional somatotrophs and GHRH receptor density
- MK-677 suitable for subjects with pituitary dysfunction; Sermorelin contraindicated in such cases
- Appetite Effect
- Significant appetite stimulation (ghrelin mimetic effect)
- Minimal appetite impact
- MK-677 reliably increases hunger; Sermorelin does not
- Research Applications
- Studies requiring oral administration, sustained GH elevation, or pituitary-independent GH secretion
- Studies investigating pituitary reserve, age-related GH decline, or physiological GH pulsatility
- Select MK-677 for mechanistic simplicity; Sermorelin for physiological fidelity